Yazar "Erenler, Ayse Sebnem" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Comparative Analysis of Antioxidant, Anticholinesterase, and Antibacterial Activity of Microbial Chondroitin Sulfate and Commercial Chondroitin Sulfate
    (Wiley-V C H Verlag Gmbh, 2023) Unver, Tuba; Erenler, Ayse Sebnem; Bingul, Murat; Boga, Mehmet
    Chondroitin synthesis was performed using the recombinant Escherichia coli(C2987) strain created by transforming the plasmid pETM6-PACF-vgb, which carries the genes responsible for chondroitin synthesis, kfoA, kfoC, kfoF, and the Vitreoscilla hemoglobin gene (vgb). Then, Microbial chondroitin sulfate (MCS)'s antioxidant, anticholinesterase, and antibacterial activity were compared with commercial chondroitin sulfate (CCS). The antioxidant studies revealed that the MCS and CCS samples could be potential targets for scavenging radicals and cupric ion reduction. MCS demonstrated better antioxidant properties in the ABTS assay with the IC50 value of 0.66 mg than CCS. MCS showed 2.5-fold for DPPH and almost 5-fold for ABTS(center dot)+ (with a value of 3.85 mg/mL) better activity than the CCS. However, the compounds were not active for cholinesterase enzyme inhibitions. In the antibacterial assay, the Minimum inhibitory concentration (MIC) values of MCS against S. aureus, E. aerogenes, E. coli, P. aeruginosa, and K. pneumoniae (0.12, 0.18, 0.12, 0.18, and 0.18 g/mL, respectively) were found to be greater than that of CCS (0.42, 0.48, 0.36, 0.36, and 0.36 g/mL, respectively). This study demonstrates that MCS is a potent pharmacological agent due to its physicochemical properties, and its usability as a therapeutic-preventive agent will shed light on future studies.
  • Küçük Resim Yok
    Öğe
    Electrospun Polycaprolactone (PCL)/Microbial Chondroitin Sulfate (CS)-Based Transdermal Patches for Optimized Ribociclib Delivery
    (Amer Chemical Soc, 2025) Gunduz Tavlar, Nermin; Balcioglu, Sevgi; Erenler, Ayse Sebnem; Ates, Burhan
    Breast cancer remains the most prevalent cancer worldwide and a leading cause of mortality in women, demanding advanced drug delivery strategies. Ribociclib, a CDK4/6 inhibitor used in hormone-dependent breast cancer therapy, is effective but requires high oral doses, leading to severe systemic toxicity. To overcome this limitation, we developed electrospun PCL/CS-based transdermal patches designed to enhance drug bioavailability, prolong half-life, and minimize side effects. Extensive characterization confirmed the structural integrity and performance of the patches, demonstrating high swelling capacity (81-93%), superior thickness uniformity (95-100%), and exceptional folding endurance (1000-1540 cycles). The patches exhibited excellent weight homogeneity (92-99%) for consistent drug distribution, while adhesion strength (144-386 kPa) ensured stable skin attachment. HPLC analysis revealed sustained Ribociclib release (similar to 95% over 48 h), and ex vivo rat skin diffusion studies confirmed high permeability (68-81%), indicating effective transdermal absorption. Drug retention efficiency exceeded 95% in both the reservoir and drug release layers. Biocompatibility assessments with L-929 fibroblasts demonstrated excellent cell viability (90-95%), while MCF-7 breast cancer cells exhibited potent cytotoxicity (93-94%), comparable to standard Ribociclib treatment. Despite the therapeutic potential of transdermal drug delivery systems (TDDS), Ribociclib has been scarcely explored in this context. This study pioneers a promising alternative for controlled, sustained drug release, potentially revolutionizing breast cancer treatment by improving patient compliance, reducing systemic toxicity, and enhancing therapeutic outcomes.